Literature DB >> 2076728

Yohimbine bioavailability in humans.

S K Guthrie1, M Hariharan, L J Grunhaus.   

Abstract

Pharmacokinetic profiles were determined in seven healthy young male subjects following single oral and intravenous doses of 10 mg of yohimbine hydrochloride. The drug was rapidly eliminated (t1/2 beta 0.58 h orally and t1/2 beta 0.68 h intravenously). Following intravenous administration the data fit a two-compartment pharmacokinetic model, with a very rapid distribution phase (t1/2a was approximately 6 min). Both the oral and the intravenous yohimbine clearance values were high but oral clearance values were much higher (mean 9.77 ml.min-1.kg-1 intravenous versus 55.9 ml.min-1.kg-1 oral). The oral bioavailability showed great variability, ranging from 7% to 87% (mean value was 33%). The incomplete oral bioavailability of yohimbine may reflect either incomplete absorption from the gastrointestinal tract or an hepatic first pass effect. Although yohimbine is rapidly absorbed when given orally, the bioavailability is quite variable and considerable individualization of dosing may be necessary when the drug is used orally for clinical indications.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2076728     DOI: 10.1007/BF00315421

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Nonhormonal pharmacological treatment of organic impotence.

Authors:  A Morales; D H Surridge; P G Marshall; J Fenemore
Journal:  J Urol       Date:  1982-07       Impact factor: 7.450

2.  Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks.

Authors:  D S Charney; S W Woods; W K Goodman; G R Heninger
Journal:  Am J Psychiatry       Date:  1987-08       Impact factor: 18.112

3.  Evidence supporting the existence of presynaptic alpha-adrenoceptors in the regulation of endogenous noradrenaline release upon hepatic sympathetic nerve stimulation in the dog liver in vivo.

Authors:  N Yamaguchi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

4.  The pharmacokinetics of yohimbine in man.

Authors:  J A Owen; S L Nakatsu; J Fenemore; M Condra; D H Surridge; A Morales
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Assessment of alpha 2 adrenergic autoreceptor function in humans: effects of oral yohimbine.

Authors:  D S Charney; G R Heninger; D E Sternberg
Journal:  Life Sci       Date:  1982-06-07       Impact factor: 5.037

6.  Double-blind trial of yohimbine in treatment of psychogenic impotence.

Authors:  K Reid; D H Surridge; A Morales; M Condra; C Harris; J Owen; J Fenemore
Journal:  Lancet       Date:  1987-08-22       Impact factor: 79.321

7.  Oral yohimbine in human autonomic failure.

Authors:  J Onrot; M R Goldberg; I Biaggioni; R G Wiley; A S Hollister; D Robertson
Journal:  Neurology       Date:  1987-02       Impact factor: 9.910

8.  Effect of yohimbine on blood pressure in patients with depression and orthostatic hypotension induced by clomipramine.

Authors:  L Lacomblez; G Bensimon; F Isnard; B Diquet; Y Lecrubier; A J Puech
Journal:  Clin Pharmacol Ther       Date:  1989-03       Impact factor: 6.875

9.  Pharmacologic and tracer methods to study sympathetic function in primary hypertension.

Authors:  D S Goldstein; G Eisenhofer; M Garty; F L Sax; H R Keiser; I J Kopin
Journal:  Clin Exp Hypertens A       Date:  1989
  9 in total
  10 in total

1.  Effect of 3 weeks treatment with yohimbine on salivary secretion in healthy volunteers and in depressed patients treated with tricyclic antidepressants.

Authors:  H Bagheri; L Schmitt; M Berlan; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

Review 2.  Commercially marketed supplements for bodybuilding athletes.

Authors:  K K Grunewald; R S Bailey
Journal:  Sports Med       Date:  1993-02       Impact factor: 11.136

3.  Involvement of selective alpha-2 adrenoreceptor in sympathetically maintained pain.

Authors:  Chan Hong Park; An Yong; Sang Ho Lee
Journal:  J Korean Neurosurg Soc       Date:  2010-06-30

4.  Alpha 2-adrenoceptor antagonist potencies of two hydroxylated metabolites of yohimbine.

Authors:  M Berlan; R Le Verge; J Galitzky; P Le Corre
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

5.  Pharmacokinetic study of yohimbine and its pharmacodynamic effects on salivary secretion in patients treated with tricyclic antidepressants.

Authors:  H Bagheri; P Picault; L Schmitt; G Houin; M Berlan; J L Montastruc
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

6.  The relationship between resting blood pressure and acute pain sensitivity: effects of chronic pain and alpha-2 adrenergic blockade.

Authors:  Stephen Bruehl; Ok Y Chung; Laura Diedrich; André Diedrich; David Robertson
Journal:  J Behav Med       Date:  2007-10-17

7.  CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications.

Authors:  Anna Mueller-Schoell; Robin Michelet; Ferdinand Weinelt; Charlotte Kloft; Gerd Mikus
Journal:  Arch Toxicol       Date:  2021-05-24       Impact factor: 5.153

8.  Yohimbine-induced amygdala activation in pathological gamblers: a pilot study.

Authors:  Igor Elman; Lino Becerra; Evelyne Tschibelu; Rinah Yamamoto; Edward George; David Borsook
Journal:  PLoS One       Date:  2012-02-02       Impact factor: 3.240

Review 9.  Sexual enhancement products for sale online: raising awareness of the psychoactive effects of yohimbine, maca, horny goat weed, and Ginkgo biloba.

Authors:  Ornella Corazza; Giovanni Martinotti; Rita Santacroce; Eleonora Chillemi; Massimo Di Giannantonio; Fabrizio Schifano; Selim Cellek
Journal:  Biomed Res Int       Date:  2014-06-15       Impact factor: 3.411

10.  Oral Yohimbine as a New Probe Drug to Predict CYP2D6 Activity: Results of a Fixed-Sequence Phase I Trial.

Authors:  Manuela Vay; Marleen Julia Meyer; Antje Blank; Gisela Skopp; Peter Rose; Mladen Vassilev Tzvetkov; Gerd Mikus
Journal:  Clin Pharmacokinet       Date:  2020-07       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.